- Home
- TRVI
as 04-18-2025 1:44pm EST
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 383.4M | IPO Year: | 2019 |
| Target Price: | $17.56 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $7.39 | Next Earning Date: | 05-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Trevi Therapeutics Inc. (TRVI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SCIASCIA THOMAS | TRVI | Chief Scientific Officer | Mar 25 '25 | Sell | $6.60 | 2,631 | $17,364.60 | 221,373 | |
| GOOD JENNIFER L | TRVI | President & CEO | Mar 21 '25 | Sell | $6.58 | 5,263 | $34,624.75 | 213,313 | |
| Simon Farrell | TRVI | Chief Commercial Officer | Mar 10 '25 | Sell | $6.94 | 81,313 | $548,877.91 | 81,250 |
Latest Trevi Therapeutics Inc. News
TRVI Breaking Stock News: Dive into TRVI Ticker-Specific Updates for Smart Investing
PR Newswire
16 days ago
Trevi Therapeutics to Participate in Upcoming April Investor Conferences
GlobeNewswire
24 days ago
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
MT Newswires
a month ago
B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating
Thomson Reuters StreetEvents
a month ago
Q4 2024 Trevi Therapeutics Inc Earnings Call
GuruFocus.com
a month ago
Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing ...
PR Newswire
a month ago
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
Simply Wall St.
a month ago
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week
PR Newswire
a month ago
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
Compare TRVI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRVI Trevi Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.